Viking Therapeutics Share Price Today

UBS initiates coverage on Viking Therapeutics with Buy rating, $94 target

UBS initiated coverage on Viking Therapeutics with a Buy rating. Analyst Joon Lee assigned a price target of $94 per share. The rating marks the start of formal brokerage tracking for the company.

Viking Therapeutics initiates SUNRISE Phase 3 program for oral VK2735

Viking Therapeutics initiates SUNRISE Phase 3 program for oral VK2735. Two studies target 560 adults each for obesity and type 2 diabetes. Primary endpoint is percent change in body weight after 68 weeks. Doses tested include 27.5 mg, 35 mg, and 55 mg against placebo.

Viking Therapeutics closes upsized offerings, raises $575 million gross

Viking Therapeutics closed concurrent upsized offerings on September 28, 2026, raising gross proceeds of approximately $575.0 million. Final common stock tranche totalled 9,035,714 shares at $35.00 per share, including full exercise of the 1,178,571-share over-allotment option. Convertible senior notes reached $258.75 million aggregate principal at 2.00% coupon due 2032, including full exercise of the $33.75 million over-allotment. Net proceeds estimated at approximately $547.8 million, to fund VK2735 and VK3019 clinical programs and general corporate purposes. Shares had fallen 15.61% to $35.15 at pricing; Viking held $502 million in cash and short-term investments as of June 30.

Kuehn Law probes Viking Therapeutics for potential self-dealing

Kuehn Law investigates Viking Therapeutics for potential self-dealing. Officers and directors suspected of breaching fiduciary duties. Shareholders may seek damages and corporate governance reforms. Consultation and case costs covered by the law firm.

Viking Therapeutics stock rises 40% as VK2735 shows weight loss retention

Viking Therapeutics shares rose over 40% in two days following positive VK2735 data. VK2735 showed 22% placebo-adjusted weight loss at week 33 with weekly 17.5 mg dosing. Up to 97% of weight loss was maintained with every-other-week dosing schedules. Stock closed at $41.65, near its 51-week high of $43.15, amid competitor trial failures.

Viking Therapeutics shares drop 5.2% to $29.90 amid broader risk-off session

Viking Therapeutics (VKTX) shares fell 5.20% to $29.90 on Tuesday. The Nasdaq slipped 0.63% and the S&P 500 shed 0.45% in a risk-off session. VKTX trades 10% below its 20-day average but maintains a July golden cross. Healthcare sector up more than 11% over the past 90 days. Company secured capacity for 100 million injectors and 1 billion tablets.